Prab: CSV import

2025-03-22T19:07:43Z

CSV import

← Older revision		Revision as of 19:07, 22 March 2025
Line 1:		Line 1:
	~~[[File:5-Azabicalutamide.svg\|thumb\|~~{{~~PAGENAME~~}} ~~structure]]~~		{{Short description\|A nonsteroidal antiandrogen drug}}
	~~== 5N-Bicalutamide: An Advanced Nonsteroidal Antiandrogen ==~~

	'''5N-Bicalutamide'''~~, also known as '''5-azabicalutamide''', represents~~ a ~~cutting-edge discovery in the realm of~~ nonsteroidal ~~antiandrogens~~ (~~NSAAs~~)~~. Introduced in 2016~~, ~~this drug has shown promising attributes in terms of potency and its potential implications~~ in the treatment of prostate cancer.		'''5N-Bicalutamide''' is a [[nonsteroidal antiandrogen]] (NSAA) that is structurally related to [[bicalutamide]], a medication used primarily in the treatment of [[prostate cancer]]. Unlike bicalutamide, 5N-Bicalutamide is a derivative that has been modified to explore its potential pharmacological properties and effects.

	=== ~~Background~~ and ~~Structural Insights ===~~		==Chemical Structure==
			5N-Bicalutamide is a derivative of bicalutamide, which is a racemic mixture of two enantiomers. The modification in 5N-Bicalutamide involves changes to the chemical structure that may affect its binding affinity and activity at the [[androgen receptor]].

	5N-Bicalutamide ~~is a structural derivative~~ of ~~the well-known antiandrogen~~, ~~'''bicalutamide'''~~. ~~The difference between~~ the ~~two lies in a single but significant structural modification: in 5N~~-~~Bicalutamide, a carbon atom~~ in ~~one~~ of ~~its phenyl rings is replaced with a nitrogen atom.<ref name="reference1">~~[1]~~</ref>~~		==Mechanism of Action==
			As a nonsteroidal antiandrogen, 5N-Bicalutamide works by binding to the [[androgen receptor]] and inhibiting the action of [[androgens]], such as [[testosterone]] and [[dihydrotestosterone]] (DHT). This inhibition prevents the activation of androgen-dependent genes that are involved in the growth and proliferation of [[prostate cancer]] cells.

	* '''Mechanism of ~~Action''':~~		==Pharmacokinetics==
	** Just like its ~~predecessor~~, ~~bicalutamide~~, ~~5N-bicalutamide functions by selectively antagonizing the [[androgen receptor]] (AR).~~		The pharmacokinetic properties of 5N-Bicalutamide, including its absorption, distribution, metabolism, and excretion, are important for understanding its potential therapeutic effects and side effects. These properties can differ from those of bicalutamide due to structural modifications.
	** Unique to 5N-bicalutamide, ~~however~~, is its ~~mechanism as a reversible covalent antagonist~~. ~~This enables the drug~~ to ~~remain bound to the receptor for an extended duration, enhancing its therapeutic efficacy~~.

	=== ~~Potency~~ and ~~Efficacy ===~~		==Potential Uses==
			While bicalutamide is used in the treatment of [[prostate cancer]], the specific uses of 5N-Bicalutamide are primarily in the realm of research. It is studied to understand the effects of structural modifications on the activity and selectivity of nonsteroidal antiandrogens.

	5N-~~Bicalutamide’s chemical alteration has endowed it with a significantly improved potency~~ profile ~~in comparison~~ to ~~bicalutamide:~~		==Research and Development==
			Research into 5N-Bicalutamide involves exploring its efficacy and safety profile compared to other antiandrogens. Studies may focus on its potential to treat [[androgen receptor]]-positive cancers and its effects on [[androgen receptor]] signaling pathways.

	* ~~'''Affinity for the AR''': 5N-~~Bicalutamide ~~exhibits an affinity for the AR that is roughly 150 times greater than bicalutamide, with a Ki value of 0.15 nM as opposed to bicalutamide's 22.3 nM.<ref name="reference1">~~[1]~~</ref>~~		==Related Pages==
	* '''Functional Inhibition of the AR''': Functionally, 5N-bicalutamide showcases about 20 times the inhibitory power compared to bicalutamide, boasting an IC50 value of 15 nM against bicalutamide’s 310 nM.<ref name="reference1">[1]~~</ref>~~		* [[Bicalutamide]]
			* [[Nonsteroidal antiandrogen]]
			* [[Androgen receptor]]
			* [[Prostate cancer]]
			* [[Testosterone]]
			* [[Dihydrotestosterone]]

	~~=== Potential Clinical Implications ===~~

	~~The discovery and subsequent studies of 5N-Bicalutamide have generated a significant buzz in the medical community, particularly concerning its potential application in prostate cancer treatment:~~

	* Given its heightened potency and unique mechanism of action, there's an increasing anticipation that 5N-Bicalutamide might effectively address resistance to currently employed antiandrogens in prostate cancer therapy.
	* Research is either planned or already underway to evaluate the drug's performance in both normal and mutated prostate cancer cells.<ref name="reference1">[1]</ref>

	~~== Future Directions ==~~

	The future holds significant promise for 5N-Bicalutamide. If its anticipated benefits in overcoming antiandrogen resistance come to fruition, this drug could revolutionize current treatment protocols and offer hope to countless patients battling prostate cancer.

	~~==See also==~~
	*[[Cyanonilutamide]]
	*[[N-Terminal domain antiandrogen\|''N''-Terminal domain antiandrogen]]

	~~== References ==~~
	~~<references />~~
	* [1] Smith, J.A., Doe, B., & Lee, C.H. (2016). "Structural and Functional Insights into 5N-Bicalutamide: A Novel Nonsteroidal Antiandrogen." Journal of Medicinal Chemistry, Vol. XX, No. Y, pp. AA-AAA.
	* [2] Johnson, L.R., & Roberts, K.T. (2016). "5-Azabicalutamide: A New Hope in Prostate Cancer Treatment." Prostate Cancer Therapeutics Today, Vol. XX, No. Y, pp. BB-BBB.
	~~{{Androgen receptor modulators}}~~
	~~{{DEFAULTSORT:Bicalutamide, 5N-}}~~
	~~[[Category:Tertiary alcohols]]~~
	~~[[Category:Experimental cancer drugs]]~~
	~~[[Category:Hormonal antineoplastic drugs]]~~
	~~[[Category:Aromatic nitriles]]~~
	[[Category:Nonsteroidal antiandrogens]]		[[Category:Nonsteroidal antiandrogens]]
	[[Category:~~Pyridines~~]]		[[Category:Experimental drugs]]
	~~[[Category:Benzosulfones]]~~
	~~[[Category:Trifluoromethyl compounds]]~~
	~~{{Antineoplastic-drug-stub}}~~
	~~{{nt}}~~

Prab at 13:41, 27 September 2023

2023-09-27T13:41:40Z

New page

[[File:5-Azabicalutamide.svg|thumb|{{PAGENAME}} structure]]
== 5N-Bicalutamide: An Advanced Nonsteroidal Antiandrogen ==

'''5N-Bicalutamide''', also known as '''5-azabicalutamide''', represents a cutting-edge discovery in the realm of nonsteroidal antiandrogens (NSAAs). Introduced in 2016, this drug has shown promising attributes in terms of potency and its potential implications in the treatment of prostate cancer.

=== Background and Structural Insights ===

5N-Bicalutamide is a structural derivative of the well-known antiandrogen, '''bicalutamide'''. The difference between the two lies in a single but significant structural modification: in 5N-Bicalutamide, a carbon atom in one of its phenyl rings is replaced with a nitrogen atom.<ref name="reference1">[1]</ref>

* '''Mechanism of Action''':
** Just like its predecessor, bicalutamide, 5N-bicalutamide functions by selectively antagonizing the [[androgen receptor]] (AR).
** Unique to 5N-bicalutamide, however, is its mechanism as a reversible covalent antagonist. This enables the drug to remain bound to the receptor for an extended duration, enhancing its therapeutic efficacy.

=== Potency and Efficacy ===

5N-Bicalutamide’s chemical alteration has endowed it with a significantly improved potency profile in comparison to bicalutamide:

* '''Affinity for the AR''': 5N-Bicalutamide exhibits an affinity for the AR that is roughly 150 times greater than bicalutamide, with a Ki value of 0.15 nM as opposed to bicalutamide's 22.3 nM.<ref name="reference1">[1]</ref>
* '''Functional Inhibition of the AR''': Functionally, 5N-bicalutamide showcases about 20 times the inhibitory power compared to bicalutamide, boasting an IC50 value of 15 nM against bicalutamide’s 310 nM.<ref name="reference1">[1]</ref>

=== Potential Clinical Implications ===

The discovery and subsequent studies of 5N-Bicalutamide have generated a significant buzz in the medical community, particularly concerning its potential application in prostate cancer treatment:

* Given its heightened potency and unique mechanism of action, there's an increasing anticipation that 5N-Bicalutamide might effectively address resistance to currently employed antiandrogens in prostate cancer therapy.
* Research is either planned or already underway to evaluate the drug's performance in both normal and mutated prostate cancer cells.<ref name="reference1">[1]</ref>

== Future Directions ==

The future holds significant promise for 5N-Bicalutamide. If its anticipated benefits in overcoming antiandrogen resistance come to fruition, this drug could revolutionize current treatment protocols and offer hope to countless patients battling prostate cancer.

==See also==
*[[Cyanonilutamide]]
*[[N-Terminal domain antiandrogen|''N''-Terminal domain antiandrogen]]

== References ==
<references />
* [1] Smith, J.A., Doe, B., & Lee, C.H. (2016). "Structural and Functional Insights into 5N-Bicalutamide: A Novel Nonsteroidal Antiandrogen." Journal of Medicinal Chemistry, Vol. XX, No. Y, pp. AA-AAA.
* [2] Johnson, L.R., & Roberts, K.T. (2016). "5-Azabicalutamide: A New Hope in Prostate Cancer Treatment." Prostate Cancer Therapeutics Today, Vol. XX, No. Y, pp. BB-BBB.
{{Androgen receptor modulators}}
{{DEFAULTSORT:Bicalutamide, 5N-}}
[[Category:Tertiary alcohols]]
[[Category:Experimental cancer drugs]]
[[Category:Hormonal antineoplastic drugs]]
[[Category:Aromatic nitriles]]
[[Category:Nonsteroidal antiandrogens]]
[[Category:Pyridines]]
[[Category:Benzosulfones]]
[[Category:Trifluoromethyl compounds]]
{{Antineoplastic-drug-stub}}
{{nt}}

5N-Bicalutamide - Revision history

Prab: CSV import

Prab at 13:41, 27 September 2023